Asia Pacific Antibody Drug Conjugates Market Forecast to 2030
Asia Pacific Antibody Drug Conjugates Market Forecast to 2030 – Regional Analysis – By Technology (Cleavable Linker and Non-cleavable Linker), Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Urothelial Cancer, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Rising Need for AI in Consent Management Fuels the Asia Pacific Antibody Drug Conjugates Market
Rising cancer incidences are primarily leading to the increasing demand for innovative cancer treatments. As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, there were 19.3 million cancer cases across the globe. China, and India were among the countries leading in cancer cases. The GLOBOCAN has also estimated that the cancer cases in India will be ~2.08 million by 2040, representing a rise of 57.5% from 2020. Similarly, as per the World Health Organization (WHO) data published in February 2022, ~10 million people have died from cancer. The most commonly seen cancer types were lung, breast, colon and rectum, prostate, and breast. The rising incidences of cancer have raised concerns worldwide. Below is the list of common cancer cases reported worldwide in 2020.
Table 1. New Cancer Cases Worldwide, in 2020
Sr. No. Cancer Type Number of Cases (Million)
1 Stomach 1.09
2 Skin (non-melanoma) 1.2
3 Prostate 1.41
4 Colon and Rectum 1.93
5 Lung 2.21
6 Breast 2.26
Cancer is now a lifestyle disease commonly seen among people with unhealthy food habits and who are physically inactive. Also, the consumption of alcohol and tobacco adds up to the risk of developing cancer. Chronic infectious diseases in low- and middle-income countries can further aggravate the cancer risk factors. According to the WHO data published in February 2022, chronic infectious diseases such as human papillomavirus (HPV), Helicobacter pylori, hepatitis B virus, hepatitis C virus, and Epstein-Barr virus attributed to nearly 18% of the diagnosed in 2018. Also, promising results of ADCs are anticipated to accelerate their demand as an effective cancer treatment and propel the market growth.
Asia Pacific Antibody Drug Conjugates Market Overview
The Asia Pacific antibody drug conjugates (ADCs) market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The growth of the ADCs market is widely driven by company collaborations, growing incidences of cancer, and increasing clinical trials.
The leading companies in Asia Pacific countries that are involved in developing ADCs have pipeline products to be launched in the market after completing the clinical trials. In June 2023, RemeGen Co., Ltd. signed an agreement with Innovent Biologics, Inc. to enter clinical trials and supply combination therapies TYVYT (sintilimab injection) with RC88, a novel mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), or TYVYT with RC108, a novel c-Met-targeting ADC. These are claimed to be novel therapies to treat solid tumors. Under the agreement, RemeGen Co., Ltd will conduct Phase 1/2a clinical studies for TYVYT to evaluate the anti-tumor activity and safety. The company also has Distamab vedotin (RC48) +PD1 combination in the pipeline. The combination is evaluated in two phases for different cancer indications, first combination is in phase III, evaluated to treat urothelial cancer in and second is in phase II, evaluated to treat muscle invasive bladder and gastric cancer.
In addition, Japanese companies are introducing breakthrough products that are expected to dominate the ADCs market. In June 2021, Daiichi Sankyo Company, Limited, and AstraZeneca plc launched Enhertu-a novel class of ADCs developed to treat HER2-low breast cancer patients. Daiichi Sankyo Company, Limited reported a year-on-year sales growth of 156.6% in the first quarter of 2023 by combining the US and European sales. Such a huge growth in the company’s sales has significantly contributed to the ADCs market size in the country and is estimated to grow exponentially in the coming years.
Asia Pacific Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Antibody Drug Conjugates Market Segmentation
The Asia Pacific antibody drug conjugates market is segmented based on technology, application, distribution channel, and country.
Based on technology, the Asia Pacific antibody drug conjugates market antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held a larger share in 2022.
Based on application, the Asia Pacific antibody drug conjugates market antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held the largest share in 2022.
Based on distribution channel, the Asia Pacific antibody drug conjugates market antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share in 2022.
Based on country, the Asia Pacific antibody drug conjugates market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Japan dominated the Asia Pacific antibody drug conjugates market in 2022.
Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd are some of the leading companies operating in the Asia Pacific antibody drug conjugates market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the Asia Pacific antibody drug conjugates market was valued at US$ 1,532.83 million in 2022 and is expected to reach US$ 6,971.03 million by 2030, registering a CAGR of 20.8% from 2022 to 2030. Increasing investments to develop ADCs and increasing FDA approvals are among the critical factors attributed to the Asia Pacific antibody drug conjugates market expansion.
ADCs are a game changer in the field of oncology; these are widely accepted for treating breast cancer. Several companies are making huge investments to develop novel ADCs. In May 2022, Evotec SE announced a huge strategic equity investment in Tubulis GmbH to develop ADCs. Evotec SE has invested US$ 64 million ( 60 million) during Tubliss Series B financing round, which is led by Andera Partners.
According to an article, Antibody-Drug Conjugates: Increasing Investment In R&D And Partnership, published in February 2023, ~63% of ADC developers would actively seek funds and investments in 2023. While ~34% of ADCs will enter into strategic mergers and acquisitions for ADC developments, nearly 56% of companies will make acquisitions of ADC developers. The investments have created broader opportunities for the Asia Pacific antibody drug conjugates market. According to the Hanson Wade Analytics, 57 ADCs entered phase I clinical trials in 2022, accounting for an increase of 20 ADCs from 2021. Moreover, companies are making huge profits through their commercialized products, contributing to market growth for ADCs. For instance, Gilead Sciences, Inc. has gained US$ 22 million in the first quarter of 2023 for its Trodelvy (Sacituzumab govitecan-hziy) that treats HER2-negative metastatic breast cancer. It has experienced an increase of 52% compared to 2022. The increase in profits is also expected to enhance strategic investments and decisions that would expand the market growth shortly.
On the contrary, high cost of ADCs development and commercialization hampers the growth Asia Pacific antibody drug conjugates market.
Based on technology, the Asia Pacific antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held 64.9% share of the Asia Pacific antibody drug conjugates market in 2022, amassing US$ 994.58 million. It is projected to garner US$ 4,462.29 million by 2030 to expand at 20.6% CAGR during 2022-2030.
Based on application, the Asia Pacific antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held 57.0% share of the Asia Pacific antibody drug conjugates market in 2022, amassing US$ 873.76 million. It is projected to garner US$ 4,091.37 million by 2030 to expand at 21.3% CAGR during 2022-2030.
Based on distribution channel, the Asia Pacific antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 70.6% share of Asia Pacific antibody drug conjugates market in 2022, amassing US$ 1,082.65 million. It is projected to garner US$ 5,044.13 million by 2030 to expand at 21.2% CAGR during 2022-2030.
Based on country, the Asia Pacific antibody drug conjugates market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Japan held 49.1% share of Asia Pacific antibody drug conjugates market in 2022, amassing US$ 752.62 million. It is projected to garner US$ 3,453.45 million by 2030 to expand at 21.0% CAGR during 2022-2030.
Key players operating in the Asia Pacific antibody drug conjugates market are Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd, among others.
– In Mar 2023, Pfizer Inc. and Seagen Inc entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.
– In Sept 2023, Seagen Inc., a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and RemeGen Co., Ltd. have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC. This collaboration leverages Seagens world-class expertise and knowledge of ADC development, manufacturing, and commercialization to maximize the potential of disitamab vedotin.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific antibody drug conjugates market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Antibody Drug Conjugates Market – Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
4.1.2 Rising Incidences of Cancer Cases
4.1.3 Increasing FDA Approvals for ADCs
4.2 Market Restraints
4.2.1 High Cost of ADCs Development and Commercialization
4.3 Market Opportunities
4.3.1 Increasing Investments to Develop ADCs
4.4 Market Trends
4.4.1 Escalating Pipeline of ADCs
4.5 Impact Analysis:
5. Antibody Drug Conjugates Market – Asia Pacific Market Analysis
5.1 Asia Pacific Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 – 2030
6. Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Technology
6.1 Overview
6.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
6.3 Cleavable Linker
6.3.1 Overview
6.3.2 Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Non-cleavable Linker
6.4.1 Overview
6.4.2 Non-cleavable Linker: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Application
7.1 Overview
7.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Blood Cancer
7.3.1 Overview
7.3.2 Blood Cancer: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Breast Cancer
7.4.1 Overview
7.4.2 Breast Cancer: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Ovarian Cancer
7.5.1 Overview
7.5.2 Ovarian Cancer: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Urothelial Cancer
7.6.1 Overview
7.6.2 Urothelial Cancer: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
8.4.1 Overview
8.4.2 Retail Pharmacies: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Antibody Drug Conjugates Market – Country Analysis
9.1 Asia Pacific Antibody Drug Conjugates Market, Revenue and Forecast To 2030
9.1.1 Overview
9.1.2 Asia Pacific Antibody Drug Conjugates Market Breakdown, by key Country – Revenue (2022) (US$ Million)
9.1.3 Asia Pacific: Antibody Drug Conjugates Market, by Country
9.1.3.1 China
9.1.3.1.1 Overview
9.1.3.1.2 China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.3 China: Antibody Drug Conjugates Market, by Technology
9.1.3.1.4 China: Antibody Drug Conjugates Market, by Application
9.1.3.1.5 China: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.2 Japan
9.1.3.2.1 Overview
9.1.3.2.2 Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.3 Japan: Antibody Drug Conjugates Market, by Technology
9.1.3.2.4 Japan: Antibody Drug Conjugates Market, by Application
9.1.3.2.5 Japan: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.3 India
9.1.3.3.1 Overview
9.1.3.3.2 India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.3 India: Antibody Drug Conjugates Market, by Technology
9.1.3.3.4 India: Antibody Drug Conjugates Market, by Application
9.1.3.3.5 India: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.4 South Korea
9.1.3.4.1 Overview
9.1.3.4.2 South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.4.3 South Korea: Antibody Drug Conjugates Market, by Technology
9.1.3.4.4 South Korea: Antibody Drug Conjugates Market, by Application
9.1.3.4.5 South Korea: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.5 Australia
9.1.3.5.1 Overview
9.1.3.5.2 Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.5.3 Australia: Antibody Drug Conjugates Market, by Technology
9.1.3.5.4 Australia: Antibody Drug Conjugates Market, by Application
9.1.3.5.5 Australia: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.6 Rest of Asia Pacific
9.1.3.6.1 Overview
9.1.3.6.2 Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.6.3 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Technology
9.1.3.6.4 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Application
9.1.3.6.5 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Distribution Channel
10. Asia Pacific Antibody Drug Conjugates Market-Industry Landscape
10.1 Overview
10.2 Organic Growth Strategies
10.2.1 Overview
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Companies’ Manufacturing Capacities and Capabilities
11. Company Profiles
11.1 Pfizer Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Hoffmann-La Roche Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 GSK Plc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Gilead Sciences Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 AstraZeneca Plc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Astellas Pharma Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 RemeGen Co Ltd
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Takeda Pharmaceutical Co Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Antibody Drug Conjugates Market Segmentation
Table 2. New Cancer Cases Worldwide, in 2020
Table 3. List of FDA-Approved ADCs
Table 4. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 5. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 6. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 7. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 8. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 9. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 10. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 11. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 12. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 13. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 14. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 15. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 16. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 17. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 18. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 19. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 20. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 21. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 22. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
Table 23. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
Table 24. Glossary of Terms, Antibody Drug Conjugates Market
LIST OF FIGURES
Figure 1. Asia Pacific Antibody Drug Conjugates Market Segmentation, By Country
Figure 2. Key Insights
Figure 3. Asia Pacific Antibody Drug Conjugates Market – Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Asia Pacific Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 – 2030
Figure 6. Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 7. Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Non-Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
Figure 10. Blood Cancer: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Breast Cancer: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Ovarian Cancer: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Urothelial Cancer: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 16. Hospital Pharmacies: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Retail Pharmacies: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Online Pharmacies: Asia Pacific Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Asia Pacific Antibody Drug Conjugates, by Key Country – Revenue (2022) (US$ Million)
Figure 20. Asia Pacific: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 21. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
The List of Companies – Asia Pacific Antibody Drug Conjugates Market
1. Pfizer Inc
2. Hoffmann-La Roche Ltd
3. GSK Plc
4. Gilead Sciences Inc
5. AstraZeneca Plc
6. Astellas Pharma Inc
7. RemeGen Co Ltd
8. Takeda Pharmaceutical Co Ltd
You must be logged in to post a review.
Reviews
There are no reviews yet.